Budget Model Shows Sizable Cost Savings With the Leva Pelvic Health System

Axena Health Inc. is sharing findings from a budget impact model showing the significant cost savings associated with its female urinary incontinence (UI) treatment, the Leva Pelvic Health System.

Detailed in the Journal of Medical Economics, the model showed an average $1.07 per-member-per-month (PMPM) cost savings to health plans when the Leva system was used as a first-line UI treatment compared with current clinical practice (CCP).¹

The study analyzed 24-month health plan costs associated with treating UI in adult women receiving usual care, or CCP, compared with women using Leva as a first-line treatment for UI. The analysis was based on a representative United States commercial health plan with 1 million members.

“This analysis confirms what we have long believed—that the Leva Pelvic Health System offers not only a highly effective first-line treatment for urinary incontinence, but also meaningful cost savings for payers,” said Dr. Samantha Pulliam, M.D., chief medical officer at Axena Health. “UI can place a heavy financial and clinical burden on health plans when women are not being treated with effective first-line treatment and being escalated to more invasive and costly treatment options. Leva’s ability to deliver better patient outcomes while lowering healthcare costs is a significant step forward.”

Key findings from the analysis include:

• In a United States commercial health plan with 1 million members, 334,191 were adult women, of whom 31,438 (9.4%) were treated for UI over 24 months.¹
• The total estimated 24-month cost per treated patient was $10,447 with Leva versus $11,267 without it.^1,2
• This resulted in total projected savings of over $25.7 million over 24 months, or $1.07 PMPM.¹

The results show that patients who used Leva experienced lower utilization of high-cost and invasive treatments, such as medications or surgery, leading to measurable reductions in total medical spending.

The Leva Pelvic Health System offers a non-invasive, medication-free way for women to treat urinary incontinence (UI) and chronic fecal incontinence (FI) — at home in only five minutes every day. Combining a small U.S. Food and Drug Administration-cleared vaginal motion sensor with integrated software, the Leva System offers precise, real-time visualization of pelvic movement, progress tracking and active physician involvement, all of which support improved treatment outcomes. Available by prescription only, the Leva System has multiple clinical trials and published data from globally recognized medical centers supporting its efficacy in treating UI, including two studies in Obstetrics and Gynecology (The Green Journal), the official publication of the American College of Obstetricians and Gynecologists (ACOG).

Axena Health Inc. aims to improve the lives of women with pelvic floor disorders. Its flagship product, the Leva Pelvic Health System, offers a first-line treatment for UI and chronic fecal incontinence (FI), underreported conditions affecting more than 78 million and 12 million women in the United States alone. Axena Health’s technology enables a modern approach to supervised pelvic floor muscle training through precise visualization of movement in real time, while monitoring usage and progress.

References
¹ Hall, E., Sharma, A., Goss, T. F., & Hung, K. (2025). U.S. payer budget impact of the Leva Pelvic Health System to improve pelvic floor muscle training as first-line treatment of female urinary incontinence compare to real-world clinical practice. Journal of Medical Economics, 28(1), 637–647. https://doi.org/10.1080/13696998.2025.2494940
² The total cost for the Leva group ($10,447) includes the intervention cost of $2,100.